Market Place
Sourcing Support
Histogen Files For Chapter 11 To Wind Down, Maximize Share Offering
18 Apr 2024 //
GLOBENEWSWIRE
Histogen Announces Second Adjournment of Special Meeting of Stockholders
14 Dec 2023 //
GLOBENEWSWIRE
Histogen Announces Adjournment of Special Meeting of Stockholders
05 Dec 2023 //
GLOBENEWSWIRE
Histogen winds down after search for solutions comes up short
19 Sep 2023 //
FIERCE BIOTECH
Histogen Announces Board Approval of Complete Liquidation and Dissolution
18 Sep 2023 //
GLOBENEWSWIRE
Histogen halts last remaining programs to conserve cash
06 Jul 2023 //
FIERCE BIOTECH
Histogen to Explore Strategic Alternatives
05 Jul 2023 //
GLOBENEWSWIRE
Histogen Reports First Quarter 2023 Results and Provides Business Update
11 May 2023 //
GLOBENEWSWIRE
Histogen Announces License Agreement with Johns Hopkins University
03 Apr 2023 //
GLOBENEWSWIRE
Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use
16 Mar 2023 //
GLOBENEWSWIRE
Histogen Reports Year-End 2022 Results and Provides Business Update
09 Mar 2023 //
GLOBENEWSWIRE
Histogen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
27 Feb 2023 //
GLOBENEWSWIRE
Histogen Reports 3Q 2022 Financial Results and Provides Business Update
10 Nov 2022 //
GLOBENEWSWIRE
Histogen to Report Q2 2022 Financial Results and Provide Business Update
27 Jul 2022 //
GLOBENEWSWIRE
Histogen Announces Closing of $5M Private Placement Priced Under Nasdaq Rules
14 Jul 2022 //
GLOBENEWSWIRE
Histogen Announces $5M Private Placement Priced At-the-Market Under Nasdaq Rules
12 Jul 2022 //
GLOBENEWSWIRE
Histogen Announces 1-for-20 Reverse Stock Split
01 Jun 2022 //
GLOBENEWSWIRE
Histogen to Report First Quarter 2022 Financial Results
28 Apr 2022 //
GLOBENEWSWIRE
Histogen Announces Closing of $4.75 Million Private Placement
25 Mar 2022 //
GLOBENEWSWIRE
Histogen Announces $4.75 Million Private Placement
23 Mar 2022 //
GLOBENEWSWIRE
Histogen seeks to tear up COVID-19 R&D pact and go solo
12 Mar 2022 //
FIERCEBIOTECH
Histogen Reports Q4 and Year-End 2021 Financial Results
10 Mar 2022 //
GLOBENEWSWIRE
Histogen to Report Fourth Quarter and Year-End 2021 Financial Results
03 Mar 2022 //
GLOBENEWSWIRE
Histogen Announces Closing of $3.5 Million Private Placement
21 Dec 2021 //
GLOBENEWSWIRE
Histogen Announces $3.5 Million Private Placement
16 Dec 2021 //
GLOBENEWSWIRE
Histogen and Amerimmune Announce the Presentation of Emricasan Data in COVID-19
02 Nov 2021 //
GLOBENEWSWIRE
Histogen-Amerimmune’s drug shows effectiveness against Covid-19
16 Aug 2021 //
CLINICALTRIALSARENA
Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study
16 Aug 2021 //
GLOBENEWSWIRE
Histogen to Present at the Canaccord Genuity 41st Annual Growth Conference
29 Jul 2021 //
GLOBENEWSWIRE
Histogen Announces Initiation of HST 003 Ph1/2 Trial
30 Jun 2021 //
GLOBENEWSWIRE
Histogen and Amerimmune Announce Positive Results for Emricasan
22 Jun 2021 //
GLOBENEWSWIRE
Histogen Provides Update on its Development Programs and Pipeline Focus
03 Jun 2021 //
GLOBENEWSWIRE
Histogen and Amerimmune Report Publication on Emricasan in COVID-19
18 May 2021 //
GLOBENEWSWIRE
Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study
16 Mar 2021 //
GLOBENEWSWIRE
Histogen Announces Removal of Clinical Hold by FDA for HST-003 IND
15 Mar 2021 //
GLOBENEWSWIRE
Histogen Announces Week 26 HST-001 Study Results for the Treatment
16 Feb 2021 //
GLOBENEWSWIRE
FDA hits the brakes on Histogen`s knee cartilage therapy, asking for more info
21 Jan 2021 //
ENDPTS
Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003
19 Jan 2021 //
GLOBENEWSWIRE
Histogen Announces Filing an Investigational New Drug Application for HST-003
17 Dec 2020 //
GLOBENEWSWIRE
Histogen Announces Filing an Investigational New Drug Application for HST-003
17 Dec 2020 //
GLOBENEWSWIRE
Histogen Announces Preliminary Week 18 HST-001 Study Results
01 Dec 2020 //
GLOBENEWSWIRE
Histogen enters collaborative development and commercialization agreement
28 Oct 2020 //
PHARMABIZ
Histogen and Amerimmune Enter into a Collaborative Development Emricasan
27 Oct 2020 //
GLOBENEWSWIRE
Histogen completes patient dosing in phase 1b/2a trial of HST-001
07 Oct 2020 //
PHARMABIZ
Histogen Announces Update for its HST-002 Dermal Filler Program
29 Sep 2020 //
GLOBENEWSWIRE
Histogen Announces $2M Grant Award for Clinical Advancement of HST-003
16 Sep 2020 //
GLOBENEWSWIRE
Histogen Announces Completion of Patient Enrollment for HST 001 Ph 1b/2a Trial
14 Jul 2020 //
GLOBENEWLSWIRE
Histogen begins enrollment in phase 1b/2a trial of HST 001
02 Jun 2020 //
PHARMABIZ
Histogen Announces Successful Completion of its Merger with Conatus Pharma
27 May 2020 //
GLOBENEWSWIRE
Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program
14 May 2020 //
GLOBENEWSWIRE
Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001
11 May 2020 //
GLOBENEWSWIRE
Histogen Announces Investigational New Drug Application Amendment for HST 001
06 Apr 2020 //
GLOBENEWSWIRE
